ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CJ Biomaterials Appoints Allan Chung as CEO to Lead Company's Next Phase of Growth and Innovation

By: Newsfile

Expansion of U.S. headquarters in Woburn, MA underscores investment in talent and technical capabilities supporting the growing market for PHA biopolymers

Woburn, Massachusetts--(Newsfile Corp. - June 18, 2025) - CJ Biomaterials, Inc, a division of South Korea-based CJ BIO and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, has appointed Allan (Hyuk Sung) Chung as its new Chief Executive Officer. Mr. Chung steps into the role at a pivotal moment as the company enters its next growth phase by accelerating innovation and commercialization of its sustainable PHACT™ PHA technology.

Chung brings deep technical expertise and global leadership experience to CJ Biomaterials. He earned a master's degree in Chemical Engineering from Seoul National University and an MBA from Duke University. Chung began his career at Samsung General Chemicals and built an over 20-year track record in business development across the petrochemical, electronic materials, and battery sectors at LG Chem and LG Energy Solution. Most recently, he served as Vice President of the Business Development Group at LG Energy Solution. He succeeds Harry Jang, who led the company through an important phase of organizational growth and development that included the launch of the company's first semi-crystalline grade of PHA, PHACT™ S1000P, and first all-PHA marine biodegradable compound designed for straws, PHACT™ CB0400A.

"I feel very fortunate to be leading CJ Biomaterials and believe they have built a strong foundation of innovation, product quality, and customer trust," said Chung. "The world-class team of PHA and biopolymer experts the company has assembled is truly impressive, and I look forward to accelerating the growth of our PHACT™-branded PHA technology as we expand its applications, achieve market-leading manufacturing economics, and bring sustainable, high-performance solutions to more markets around the world."

To support the next stage of growth envisioned by Chung, CJ Biomaterials is expanding its U.S. headquarters in Woburn, MA. The larger facility includes enhanced application development capabilities, additional space for the company to expand its sales, marketing and technical teams, and new equipment that enables in-house testing of home compostable PHA-based solutions under controlled temperature settings. The expanded capabilities in Woburn, MA, will create functional collaboration opportunities with customers and value chain partners that will accelerate the adoption of sustainable packaging solutions that consumers and brands value.

"As CJ Biomaterials continues to grow and advance its technical capabilities, Chung's leadership will be instrumental in scaling our impact as we help customers transition to high-performing, sustainable biomaterials," said Seok Hwan Yoon, CEO of CJ BIO. "The Biomaterials business is a strategic component of CJ BIO's GX (Green Transformation) strategy. Chung brings a unique combination of technical depth and strategic vision that will be essential in supporting our talented global team as they advance our Green Transformation objectives."

CJ Biomaterials is seeing increased demand for its PHA biopolymers, which improve the sustainability profile of a wide range of consumer and industrial products by replacing petroleum-based plastics that persist in the environment. Producing PHACT™ PHA begins when plant feedstocks capture and sequester atmospheric carbon dioxide in sugars through the process of photosynthesis. These sugars are then fermented by bacteria to produce PHA biopolymers that have a low carbon footprint in addition to being home and commercially compostable and biodegradable in marine and soil environments. CJ Biomaterials' unique PHA technology can produce a broad range of PHA polymers from fully amorphous to semi-crystalline.

The company continues to introduce new PHA grades and compounds tailored for innovative applications in flexible and rigid food packaging, food serviceware, agriculture, and nonwovens.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/9734/255895_2e43ed5154600a2d_002.jpg

CJ Biomaterials has appointed Allan (Hyuk Sung) Chung as its new Chief Executive Officer.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9734/255895_2e43ed5154600a2d_002full.jpg

For more information on CJ Biomaterials and its mission to develop meaningful solutions that positively impact our planet and human health, visit cjbiomaterials.com or follow us on LinkedIn at @CJBiomaterials.

About CJ BIOMATERIALS
Headquartered in Woburn, MA, USA, CJ Biomaterials develops meaningful solutions that positively affect our planet, human health and well-being by addressing the challenges posed by plastic waste. The company invents and manufactures biopolymers and bio-based chemicals as part of a long-term vision to create a more sustainable future, by enabling true circular solutions that replace many non-recyclable, non-reusable and fossil fuel-based plastics and chemicals. CJ Biomaterials is a global leader in the manufacture of polyhydroxyalkanoates (PHAs) under the PHACT™ brand. CJ Biomaterials, a business unit of CJ BIO, is part of CJ CheilJedang, a global lifestyle company with a vision to inspire a new life filled with health, happiness, and convenience. To learn more about PHACT™ PHA, visit cjbiomaterials.com.

Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

CJ Biomaterials
Leah Ford
Cj.biomaterials@cj.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255895

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.